Omega Flex, Inc. Announces Second Quarter 2026 Earnings and CE Mark Approval for MediTrac Corrugated Medical Tubing
Rhea-AI Summary
Omega Flex (NASDAQ: OFLX) reported second quarter and six-month 2026 results, showing pressure on sales and earnings alongside strategic product and regulatory milestones. Net sales for the six months ended June 30, 2026 were $47.2 million, down 3.5% from $48.9 million in 2025, while net income fell to $4.8 million from $7.7 million, a 38.5% decline. For the three months ended June 30, 2026, net sales were 5.8% lower and net income was 35.6% below the prior-year quarter. The company attributed the declines mainly to lower unit volumes amid a weaker construction market and higher raw material, transportation, tariff, marketing, and product enhancement costs, partly offset by lower product liability reserves.
On July 1, 2026, Omega Flex introduced a re‑engineered TracPipe flexible gas piping fitting aimed at broader residential and commercial use, including larger diameter systems up to two inches. In August 2026, its subsidiary Flex‑Trac received CE mark certification under EU MDR 2017/745 for its patent‑protected MediTrac corrugated medical tubing (CMT) as a Class IIa device, adding to existing NFPA 99 and Canadian Z7396.1 compliance and ISO 13485:2016‑certified quality management. MediTrac CMT is already installed in healthcare facilities across 48 U.S. states, Canada, the U.K., Southeast Asia, and other markets.
Positive
- Six‑month 2026 net sales $47.2M despite suppressed construction market
- Six‑month 2026 net income $4.8M, profitable while funding product initiatives
- Launched re‑engineered TracPipe gas fitting on July 1, 2026
- MediTrac CMT obtained CE mark under EU MDR 2017/745 as Class IIa device
- MediTrac CMT installed in healthcare facilities across 48 U.S. states and multiple countries
Negative
- Six‑month 2026 net sales declined 3.5% year over year
- Six‑month 2026 net income declined 38.5% year over year
- Q2 2026 net sales were 5.8% below Q2 2025
- Q2 2026 net income was 35.6% below prior‑year quarter
- Higher raw material, transportation, tariff and marketing costs expected to continue near term
News Explained
Inventory, marketing, and capacity investments will keep adding operating spending after the second-quarter results.
The company reports that higher raw-material, transportation, tariff, and marketing costs will continue while it procures inventory and markets the new fitting, extending operating cost pressure beyond the reported results.
It also reports ongoing targeted investments in equipment and facilities to expand capacity, improve efficiency, and support geographic growth, adding continuing operating spending tied to those objectives.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | 1Q26 earnings | Negative | -6.0% | Profit declined amid higher raw material, tariff, marketing, and product enhancement costs. |
| Mar 04 | 4Q25 earnings | Negative | -16.8% | Quarterly sales and net income declined amid lower volumes and higher development expenses. |
| Oct 29 | 3Q25 earnings | Negative | -1.5% | Lower unit volumes contributed to declining quarterly sales, net income, and EPS. |
| Jul 30 | 2Q25 earnings | Negative | -1.0% | Sales increased, but quarterly and first-half net income declined year over year. |
| Apr 30 | 1Q25 earnings | Negative | -2.2% | Revenue, net income, and EPS declined amid weaker housing-related market conditions. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
OFLX's tag-specific earnings announcements produced negative 24-hour reactions in all five supplied events, averaging -5.51%.
Key Terms
ce mark certification regulatory
eu mdr 2017/745 regulatory
class iia medical device medical
iso 13485:2016 regulatory
nfpa 99 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
EXTON, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) --
| OMEGA FLEX, INC. (OFLX) | |||||||||||
| Six Months Ended June 30, | Three Months Ended June 30, | ||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||
| Net Sales | $ | 47,150,000 | $ | 48,855,000 | $ | 24,057,000 | $ | 25,525,000 | |||
| Net Income attributable to Omega Flex, Inc. | $ | 4,752,000 | $ | 7,724,000 | $ | 2,675,000 | $ | 4,156,000 | |||
| Earnings Per Share – Basic and Diluted | $ | 0.47 | $ | 0.77 | $ | 0.27 | $ | 0.41 | |||
| Weighted Average Shares – Basic and Diluted | 10,094,322 | 10,094,322 | 10,094,322 | 10,094,322 | |||||||
Dean W. Rivest, Chief Executive Officer of Omega Flex, Inc. (the “Company”), announced that net sales of the Company for the six months ended June 30, 2026 and 2025 were
Net income for the six months ended June 30, 2026 was
Approximately
During the six months ended June 30, 2026, the Company continued to pursue product enhancements intended to strengthen its market position. On July 1, 2026, the Company introduced a re-engineered flexible gas piping fitting designed to support a broader range of applications across both residential and commercial construction markets. The new TracPipe® System branded fitting is designed to ease installation while enhancing overall safety and reliability. The Company believes that in the commercial sector, the fitting is particularly well suited for larger diameter systems, including sizes up to two inches, helping to address the requirements of more demanding installations. The Company continues to make targeted investments in equipment and facilities intended to expand capacity, enhance operational efficiency, and support geographic growth by improving its ability to serve customers and distribution partners across existing and new markets.
In addition, the Company is pleased to announce that its innovative medical-grade product, MediTrac® corrugated medical tubing (CMT), received Conformité Européenne (CE) mark certification under the European Union Medical Device Regulation (EU MDR 2017/745) in August of 2026, as a Class IIa medical device. Achieving EU MDR certification, a lengthy and rigorous process, demonstrates that MediTrac CMT meets applicable European standards for safety, quality, and clinical performance.
The Company is not aware of any other manufacturers of CMT. MediTrac CMT, developed exclusively by the Company, is patent protected and complies with the stringent requirements of Health Care Facilities Code NFPA 99, Canadian Standard Z7396.1 (Medical Gas Pipeline Systems), and now, EU MDR 2017/745.
MediTrac CMT is engineered for the safe and efficient distribution of medical gases in healthcare facilities, offering a flexible, durable, and installation‑friendly alternative to traditional rigid copper tubing. It is manufactured by the Company’s subsidiary, Flex-Trac, Inc., in Exton, Pennsylvania. EU MDR compliance reflects the rigor of our design and manufacturing controls and is maintained under an ISO 13485:2016-certified quality management system. MediTrac CMT has been installed in healthcare facilities across 48 U.S. states, Canada, the United Kingdom, Southeast Asia, and other international markets.
“We are extremely proud to achieve CE mark certification for MediTrac CMT,” said Dean W. Rivest, Chief Executive Officer of Omega Flex, Inc. and President and Chief Executive Officer of Flex-Trac, Inc. “Combined with the ISO 13485:2016 quality management system certification, this milestone highlights our dedication to producing safe, reliable, and innovative medical gas tubing solutions for healthcare systems around the world. We believe MediTrac CMT has the potential to serve as a scalable growth platform that extends our engineering expertise into new geographic regions and markets while leveraging our established manufacturing and quality systems.”
INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS – This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s financial condition, results of operations, future performance, growth strategies, business initiatives and anticipated trends. Forward-looking statements can generally be identified by words such as “may,” “should,” “will,” “could,” “estimates,” “predicts,” “potential,” “continue,” “anticipates,” “believes,” “plans,” “expects,” “future,” “intends,” “projects,” the negative of these terms, or other comparable terminology. These forward-looking statements may include the Company’s projections, statements related to the Company’s anticipated growth strategies, descriptions of business initiatives and anticipated trends in the Company’s business. Forward-looking statements are neither historical facts nor assurances of future performance. Rather, they are based on current beliefs, expectations and assumptions regarding the Company’s business, strategies and anticipated events and trends. These statements are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict, many of which are outside of our control, and actual results could differ materially from those expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation, other than as required by law, to update or revise any forward-looking statements to reflect events or circumstances after the date hereof. Further information regarding risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements is included in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) and in the Company’s subsequent reports and filings with the SEC, as applicable.
Contact: Dean W. Rivest
(610) 524-7272
